ADA Medical, a Research Partnership Group of research professionals dedicated to the successful implementation and completion of clinical research projects for the pharmaceutical, biotechnology and medical device industries, is collaborating with CRO Ephoran Multi-Imaging Solutions.
Building on Ephoran’s technology, ADA Medical is expanding into the preclinical research space. ADA Medical can now provide research and quality assured based preclinical contract services focused on inflammatory, oncology and cardiovascular diseases.
This new molecular imaging CRO service based in Italy will conduct preclinical drug development modeling and assessments. ADA Medical’s existing project management, pharmacodynamics, pharmacokinetics, biostatistics, data management and regulatory/quality assurance capabilities will bring needed GLP, preclinical management and quality oversight to create the discipline needed for drug research and support of drug research submissions.
“Ephoran’s molecular imaging will bring a much needed new technology to the market to assist drug and biotech companies in expediting cost effective development of new compounds to clinical trials,” said Renzo DiCarlo, CEO of ADA Medical.
Ephoran is a reference center for a number of imaging technologies. This expansion into drug development applications fills a void in the preclinical drug imaging sector, namely new product verification prior to filing an Investigational New Drug Application (INDA).
“Imaging technology provides significant biological data that will be used to verify the efficacy of a drug compound and make the drug development process much more effective and quicker” said Vito Lorusso, vice president, Ephoran.